Search the Newsreel

(RGNX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. …

H.C. Wainwright lowers Regenxbio stock price target on equity offering

H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the development …

Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway

REGENXBIO (RGNX) experienced a nearly 5% stock drop despite reporting a surprise profit of US$0.43 EPS and US$108 million in revenue for Q2 2026, swinging from a significant loss. The company also extended its cash runway into Q4 2027 due to funding from AbbVie …

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)

REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside

Analysts have raised REGENXBIO Inc.'s average 12-month price target from $26 to $26.17, indicating a potential upside of approximately 149% from its August 5 closing price. The consensus rating for RGNX remains a "Buy" among 12 analysts, with 11 recommending a Buy and 1 …

Barclays downgrades Regenxbio stock rating on regulatory uncertainty

Barclays downgraded Regenxbio Inc. (NASDAQ:RGNX) to Equalweight from Overweight, setting a price target of $12.00 due to regulatory uncertainty surrounding its Duchenne muscular dystrophy (DMD) program and competitive landscape for wet age-related macular degeneration (wet AMD). Despite a recent 16% stock increase, the firm …

REGENXBIO (Nasdaq: RGNX) turns Q2 profit on $100M AbbVie milestone

REGENXBIO (Nasdaq: RGNX) reported a significant turnaround in Q2 2026, posting a net income of $22.7 million ($0.43 per share) compared to a $70.9 million net loss in Q2 2025. This profit was largely driven by $108.0 million in total revenues, primarily from a …

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket

REGENXBIO reported Q2 2026 adjusted EPS of $0.43, significantly beating the $0.25 forecast, though revenue of $108.02 million missed estimates. Shares rose premarket due to a strengthened balance sheet, with pro forma cash exceeding $310 million after a $100 million AbbVie milestone and a …

REGENXBIO Inc. Quarterly Earnings Report

Form 8K Regenxbio Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Regenxbio Inc. on August 6th. The content of the Form 8K itself is not detailed, but the article contextualizes it within broader financial market news and data provided by Investing.com.

REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M

REGENXBIO announced strong financial results for Q2 2026, with revenues reaching $108.0 million and net income at $22.7 million. The company's cash position, including July 2026 milestone and offering proceeds, stands at over $313 million pro forma. Key upcoming catalysts include a BLA initiation …

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward …

REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements about the development and commercialization of its gene therapy RGX‑111, …

RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap

Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and …

Regenxbio Inc expected to post earnings of 6 cents a share - Earnings Preview

Regenxbio Inc. (RGNX) is projected to report earnings of 6 cents per share. This financial forecast is provided as an earnings preview by Refinitiv. The full article is available to TradingView subscribers, offering unlimited access to news sources.

Earnings Preview: Regenxbio to Report Financial Results Pre-market on August 06

This article announces that Regenxbio Inc. (RGNX) is scheduled to release its financial results pre-market on August 6. Analysts are expecting a consensus loss per share of -$0.98. The report will likely detail the company's performance and provide insights into its gene therapy programs.

REGENXBIO's second-quarter financial update is set for Aug. 6

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide operational highlights. Investors and analysts can register for the webcast, with a …

(RGNX) Risk Channels and Responsive Allocation

This article provides a detailed analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting weak sentiment across all time horizons which supports a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …

RGNX|Regenxbio Inc|Price:10.180|Chg%:+0.060

The article provides a comprehensive stock analysis of Regenxbio Inc (RGNX) from TradingKey, highlighting its relatively weak fundamentals but significant growth potential. The stock is considered fairly valued, with high institutional ownership and multiple "Buy" ratings from analysts. The company, a clinical-stage biotechnology firm, …

REGENXBIO (RGNX) Projected to Post Earnings on Thursday

Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0

The article provides a financial snapshot of REGENXBIO, Inc. (HAM:RB0) on TradingView, specifically focusing on its diluted shares outstanding. It notes that the market for HAM:RB0 is currently closed with no trades recorded. The content seems to be a financial data placeholder, indicating where …

Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Regenxbio Inc's (RGNX) dividend and stock split history, indicating that no dividends have been distributed over the past five years. It presents current stock performance data, including its market cap and recent price change. The page is part …

Inventory turnover of REGENXBIO, Inc. – HAM:RB0

This article focuses on the inventory turnover of REGENXBIO, Inc. (HAM:RB0). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred. The content suggests the financial data provided is made by humans and …

Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Regenxbio Inc (RGNX), detailing its price momentum score, current trading range, and a summary of technical indicators and moving averages. RGNX currently has a price momentum score of 5.89 and is trading between a resistance level of …

REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX

The article provides a revenue breakdown for REGENXBIO Inc. (NASDAQ: RGNX), highlighting that the company generated $170.44 million USD last year. Its top-performing segment was Gene Therapies, contributing the entire $170.44 million, an increase from $83.33 million the previous year. Japan was the largest …

REGENXBIO Inc. (RGNX) stock price, news, quote and history

This article provides comprehensive financial data for REGENXBIO Inc. (RGNX), including its stock price, historical performance, earnings, and analyst insights. As of July 24, 2026, RGNX closed at $9.73, down 5.07%, with an after-hours price of $9.79. The company, a clinical-stage biotechnology firm, specializes …

Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.

Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on Phase I/II study …

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 trial study, specifically concerning its efficacy and …

Frontier tech research, news & data

This article reports on an 8-K filing by REGENXBIO Inc. on July 20, 2026, detailing other events. It also highlights a research report on fuel-cell deployments at U.S. data centers, indicating 154 MW of operating capacity and 6.31 GW in proposed projects across various …